{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:50:10Z","timestamp":1786971010726,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd008841.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000}}],"reference-count":43,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008841.pub3","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T11:10:58Z","timestamp":1621249858000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lacosamide add-on therapy for focal epilepsy"],"prefix":"10.1002","volume":"2021","author":[{"given":"Roshan K","family":"Babar","sequence":"additional","affiliation":[{"name":"University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bresnahan","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology; Institute of Translational Medicine, University of Liverpool; Liverpool UK"},{"name":"Department of Health Services Research, Institute of Population Health Sciences; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor S","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Institute of Systems, Molecular and Integrative Biology; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict D","family":"Michael","sequence":"additional","affiliation":[{"name":"Clinical Infection Microbiology and Neuroimmunology; Institute of Infection, Veterinary and Ecological Science; Liverpool UK"},{"name":"Department of Neurology; The Walton Centre NHS Foundation Trust; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"issue":"Suppl 6","key":"10.1002\/14651858.CD008841.pub3-BIB0001|cit1","first-page":"57, Abstract no","article-title":"Efficacy and safety of adjunctive oral lacosamide for the treatment of partial onset seizures in patients with epilepsy","volume":"46","author":"Ben Menachem","year":"2005","journal-title":"Epilepsia"},{"issue":"7","key":"10.1002\/14651858.CD008841.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008841.pub3-BIB0003|cit3","first-page":"272","article-title":"Lacosamide - efficacy and tolerability [abstract]","volume":"47","author":"Ben Menachem","year":"2006","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008841.pub3-BIB0004|cit4","first-page":"110, Abstract n","article-title":"Efficacy and safety of lacosamide as an adjunctive treatment for partial-onset seizures","volume":"50","author":"Chung","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD008841.pub3-BIB0005|cit5","first-page":"57, Abstract no","article-title":"Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial onset seizures","volume":"48","author":"Chung","year":"2007","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD008841.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD008841.pub3-BIB0007|cit7","first-page":"321, Abstract n","article-title":"Lacosamide: efficacy and safety as oral adjunctive treatment for partial onset seizures","volume":"48","author":"Chung","year":"2007","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD008841.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD008841.pub3-BIB0009|cit9","first-page":"3, Abstract no:","article-title":"Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures","volume":"47","author":"Halasz","year":"2006","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eplepsyres.2016.08.032","article-title":"Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study","volume":"127","author":"Hong","year":"2016","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0011|cit11","unstructured":"Farkas V Steinborn B Flamini J Dilley D Bozorg A Daniels T Efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal seizures: a randomized, double-blind, placebo-controlled trial Annals of Neurology 2017 82 Suppl 21 S287 90, Abstract no: 36"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD008841.pub3-BIB0012|cit12","first-page":"Abstract no: P5","article-title":"Tolerability and efficacy of adjunctive lacosamide in children and adolescents with focal seizures in context of presence or absence of sodium-channel blocking AEDs: post-hoc analysis of a randomized, double-blind, placebo-controlled trial","volume":"90","author":"Farkas","year":"2018","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0013|cit13","unstructured":"Study to investigate lacosamide as add-on therapy in subjects \u22654 years to <17 years of age with partial onset seizures clinicaltrials.gov\/ct2\/show\/NCT01921205"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Steinborn B Stockis A Zhang Y Dimova S Martin P Lack of pharmacokinetic interaction of lacosamide on carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, topiramate and valproic acid in children and adolescents with epilepsy: post-hoc analysis of a randomized, double-blind, placebo-controlled trial Neurology 2018 90 15 Suppl Abstract no: P4.270","DOI":"10.1212\/WNL.90.15_supplement.P4.270"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD008841.pub3-BIB0015|cit15","first-page":"120","article-title":"Safety and tolerability of intravenous lacosamide as replacement for oral lacosamide in subjects with partial-onset seizures","volume":"46","author":"Biton","year":"2005","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD008841.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1528-1167.2007.01317.x","article-title":"Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures","volume":"49","author":"Biton","year":"2008","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures \u2013 an open-label trial","volume":"71","author":"Ferreira","year":"2019","journal-title":"Seizure"},{"issue":"1","key":"10.1002\/14651858.CD008841.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"Grosso","year":"2014","journal-title":"European Journal of Paediatric Neurology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD008841.pub3-BIB0019|cit19","first-page":"170, Abstract n","article-title":"Evaluation of the effect of oral lacosamide on concomitant AED plasma concentrations in patients with partial seizures","volume":"46","author":"Jatuzis","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008841.pub3-BIB0020|cit20","first-page":"145","article-title":"Evaluation of the effect of oral lacosamide on adjunctive concomitant antiepileptic drug plasma concentrations in subjects with partial seizures","volume":"47","author":"Jatuzis","year":"2006","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD008841.pub3-BIB0021|cit21","first-page":"57, Abstract no","article-title":"Lacosamide in subjects with partial-onset seizures: evaluation of the effect of oral lacosamide on concomitant antiepileptic drug plasma concentrations","volume":"48","author":"Kalviainen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0022|cit22","unstructured":"Lacosamide IV and EEG\/EKG (LIVE) study (LIVE) clinicaltrials.gov\/ct2\/show\/NCT01724918"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD008841.pub3-BIB0023|cit23","first-page":"184, Abstract n","article-title":"Pharmacokinetics and safety of intravenous lacosamide administered as replacement for adjunctive oral lacosamide in patients with partial-onset seizures","volume":"46","author":"Rosenfeld","year":"2005","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD008841.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","article-title":"Global, regional, and national burden of epilepsy, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Beghi","year":"2019","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.seizure.2016.08.007","article-title":"Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs","volume":"42","author":"Brigo","year":"2016","journal-title":"Seizure"},{"issue":"6","key":"10.1002\/14651858.CD008841.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"907\u201320","DOI":"10.1007\/s10072-016-2512-2","article-title":"Dose effects of lacosamide as add-on therapy for partial-onset seizure in adult","volume":"37","author":"Chen","year":"2016","journal-title":"Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD008841.pub3-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.nurt.2006.10.002","article-title":"Lacosamide","volume":"4","author":"Doty","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0028|cit28","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0029|cit29","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0030|cit30","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S5189","article-title":"Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects and safety","volume":"5","author":"Kellinghaus","year":"2009","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"k3802","DOI":"10.1136\/bmj.k3802","article-title":"Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews","volume":"362","author":"Kirkham","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD008841.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008841.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0036|cit36","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6 (updated October 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/supplementary-materials"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0037|cit37","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"4","key":"10.1002\/14651858.CD008841.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1157.1981.tb06158.x","article-title":"Phenytoin for epilepsy: a long term prospective study, assisted by serum level monitoring, in previously untreated patients","volume":"22","author":"Reynolds","year":"1981","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD008841.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ane.12451","article-title":"Long-term adjunctive lacosamide treatment in patients with partial-onset seizures","volume":"133","author":"Rosenow","year":"2016","journal-title":"Acta Neurologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD008841.pub3-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD008841.pub3-BIB0041|cit41","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"11","key":"10.1002\/14651858.CD008841.pub3-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008841","article-title":"Lacosamide add-on therapy for partial epilepsy","author":"Shukralla","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008841.pub3-BIB0043|cit43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008841.pub2","article-title":"Lacosamide add-on therapy for partial epilepsy","author":"Weston","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T03:47:04Z","timestamp":1723175224000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008841.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008841.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}